Avicanna Hosts Symposium on Cannabinoid-based Medicine

Symposium seeks to bring Key Opinion Leaders and health care providers to explore cannabinoid-based R&D, medicine, and clinical adoption from the MaRS Discovery District, Toronto

TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company will host a medical symposium entitled “Cannabinoid-based Medicine in the Canadian Healthcare System – From Emerging Evidence to Clinical Practice” at the MaRS Discovery District, Toronto, Monday, May 13, 2024.

The symposium, with registration limited to health care practitioners and researchers, will cover a range of topics including emerging evidence and practical clinical applications of cannabinoid-based medicine. The event will feature key opinion leaders, clinicians, researchers, and scientists from various academic, research and clinical organizations and hospitals and industry. Speakers include:

		Dr. Camila Sofia Arriagada Egnen SickKids, The Hospital for Sick Children		Dr. Karolina Urban Avicanna Inc.
		Dr. Alan Bell  University of Toronto		Samantha Aitken, RPh MyMedi.ca
		Dr. Hance Clarke Toronto General Hospital University Health Network		Aras Azadian Avicanna Inc.
		Dr. Carlo DeAngelis  Sunnybrook Health Sciences Centre		Andrew Bevan Spectrum Therapeutics
		Dr. Tania Di Renna